WO1998052541A1 - Fast-dissolving tablets and methods of their manufacture by direct compression - Google Patents

Fast-dissolving tablets and methods of their manufacture by direct compression Download PDF

Info

Publication number
WO1998052541A1
WO1998052541A1 PCT/US1998/008821 US9808821W WO9852541A1 WO 1998052541 A1 WO1998052541 A1 WO 1998052541A1 US 9808821 W US9808821 W US 9808821W WO 9852541 A1 WO9852541 A1 WO 9852541A1
Authority
WO
WIPO (PCT)
Prior art keywords
grams
process according
tablet
calcium carbonate
density
Prior art date
Application number
PCT/US1998/008821
Other languages
French (fr)
Inventor
Anthony B. J. Eoga
Kirti H. Valia
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Priority to AU71726/98A priority Critical patent/AU7172698A/en
Publication of WO1998052541A1 publication Critical patent/WO1998052541A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Preparation (AREA)

Abstract

An intrabuccally dissolving and partially dissolving compressed tablets is made from low density granules. The tablets provide for the delivery of an active ingredient in an easy chew form that quickly disintegrates in the buccal cavity and dissolves in the digestive tract. The low density granules are prepared from finely divided low density forms of inactive raw material ingredients such as alkali earth metal salts and water-soluble carbohydrates. The low density granules are made by spray drying or pre-compressing raw ingredients.

Description

FAST-DISSOLVING TABLETS AND METHODS OF THEIR MANUFACTURE BY DIRECT COMPRESSION
BACKGROUND OF THE INVENTION
1. Field Of The Invention The present invention relates to intrabuccally dissolving and partially dissolving compressed tablets and a method for their manufacture. The tablets deliver an active ingredient in an easy chew form that quickly disintegrates in the buccal cavity. Particularly, the present invention relates to intrabuccally dissolving and disintegrating tablets comprised of low density granules prepared from inactive and/or active raw material ingredients. The tablets are useful in the pharmaceutical and confectionery fields. The low density granules are prepared from active and/or inactive raw material ingredients and low density ingredients such as alkali earth metal salts, water soluble carbohydrates and mixtures thereof. The present invention also comprises a process for the preparation of the low density granules, and a process for the preparation of tablets using the low density granules.
2. Description of Related Art
Compressed tablets are solid dosage forms prepared by compacting a formulation containing an active ingredient and excipients selected to aid the processing and improve the properties of the product. The term "compressed tablet" generally refers to a plain, uncoated tablet for oral ingestion, prepared by a single compression or by pre-compaction tapping followed by a final compression. Such pre-compaction tapping does not necessarily overcome the flow and die fill problems associated with the use of very fine particles prior to the final compression of the tablets. Tablets can be made in many sizes and shapes, with a variety of properties.
Tablets are the most widely used of all pharmaceutical dosage forms for a number of reasons. They are convenient, easy to use, and less expensive to manufacture than other oral dosage forms. They deliver the intended dose with a high degree of accuracy. A popular type of tablet that has been developed for special application is the buccal tablet.
Despite their benefits, buccal tablets have certain drawbacks. Foremost is the fact that buccal tablets dissolve slowly in the buccal pouch. In general, the hardness levels of compressed tablets are not adequate for fast disintegration in the buccal cavity and ultimately in the digestive tract through oral administration. This is especially disconcerting to those consumers unable to swallow or chew conventional compressed tablets. Consequently, there is a great need for a tablet that rapidly dissolves and absorbs with sufficient speed so that the tablet can be used by consumers who otherwise do not use tablets. Others have recognized and worked on the problem.
U.S. Patent No. 4,855,326, describes a melt spinnable carrier agent such as sugar combined with a medicament that is converted into fiber form by melt spinning with "cotton candy" fabricating equipment. The as-spun product is converted to compacted individual dosage units that reportedly display rapid entry into solution upon contact with a solvent.
While the melt spinnable product confers advantageous properties amenable to consumers who are unable to swallow or chew conventional compressed tablets, they are not without certain disadvantages. Most critical is that the melt spinning step is required in addition to direct compression techniques. A procedure employing only direct compression is by far the desired method from the standpoint of processing procedures, equipment and materials.
U.S. Patent No. 4,684,534 discloses tablets having a harder outer shell that inhibits penetration of liquid into the interior of the tablet. The interior of the tablet is softer and quickly liquifies when the shell is broken and the interior contacts liquid.
U.S. Patent No. 5,178,878 discloses a tablet made from microparticles and an effervescent disintegration agent. When the tablet is taken orally, the effervescent disintegration agent aids in rapid dissolution of the tablet. U.S. Patent No. 5,501,861 discloses fast dissolving tablets. The tablets have a porosity of 30 to 70%, a hardness of 3 to 20 kg and a falling impact strength of 0 to 70%. The tablets are made with water-soluble carbohydrates and 1 to 3% by weight of water. The tablets are made by adhering particles of carbohydrate to each other by moistening the surfaces of the particles with the water, compressing the particles and removing the water.
U.S. Patent No. 5,576,014 discloses an intrabuccally dissolving compressed molding made from a granulated saccharide having low moldability and a saccharide having high moldability. The blending ratio of the high moldability saccharide to the low moldability saccharide is 2 to 20% by weight. The moldings quickly disintegrate in the buccal cavity and have adequate hardness.
German Patent Document 1,617,638 teaches sorbitol for use as a tablet binder. The density of the sorbitol used is between 0.53 and 0.545 gms/cm3.
SUMMARY OF THE INVENTION
The present invention provides a rapidly dissoluble dosage unit, such as a tablet, that can be employed in both the pharmaceutical and confectionery fields. The dosage unit quickly disintegrates and partially or totally dissolves in the buccal cavity. The tablet has a hardness sufficient to retain its dosage integrity or form and is still capable of being easily chewed.
The present invention also includes a process for preparing tablets by compacting granules that are made from one or more low density alkali earth metal salts, water soluble carbohydrates or mixtures thereof. The low density alkali earth metal salts used in the granules include calcium carbonate, calcium hydroxide, magnesium carbonate, magnesium hydroxide, aluminum hydroxide, magnesium silicate, magnesium aluminate or aluminum magnesium hydroxide. The water soluble carbohydrates are preferably highly porous and can be selected from a high moldability or low moldability type. High moldability type, water soluble carbohydrates include maltose, maltitol and sorbitol. Low moldability type, water soluble carbohydrates include mannitol, glucose, sucrose and xylitol. The granules used to make the tablets according to the present invention can also be made from other raw materials including starches, proteins, maltodextrins and oligosaccharides. Additionally, there are many coated and uncoated drugs, other active ingredients, non-carbohydrate ingredients that are highly soluble in the buccal cavity and highly porous.
Although the direct use of higher density alkali earth metal salts and water soluble carbohydrates provide adequate tablet hardness levels, they do not provide for low density tablets that disintegrate quickly when chewed and have a smooth mouthfeel. Additionally, while the direct use of a low density alkali earth metal salt or water soluble carbohydrate provides for a smooth mouthfeel, it is also difficult to compress these ingredients because of their low density and fine mesh size. Although the spray drying of higher density alkali earth metal salts and water soluble carbohydrates provide adequate tablet hardness levels, they do not generally provide for low density tablets that exhibit quick disintegration in the buccal cavity and a smooth mouthfeel. Prior art spray dried tablet ingredients also exhibit a high mesh size profile (very fine particles) that does not always match the mesh size profile of a number of active and inactive ingredients. This could lead to inadequate content uniformity. However, when low density alkali earth metal salt or water soluble carbohydrate are either spray dried or pre-compacted, the resulting granules can be compressed to obtain structurally sound tablets that are easy to chew and quickly dissolve. Additionally, tablets made from the granules produce a low density product with optimal content uniformity. The present invention includes fast chewing, rapidly dissolving tablets made from granules that are prepared from a variety of raw materials. The present invention also includes processes for preparing the granules. The granules can be prepared by either spray drying or pre-compacting the ingredients. When the granules are compressed into tablets with other excipients, the resulting tablets exhibit a low density, sufficient hardness to permit for easy chew characteristics, fast disintegration, smooth mouthfeel, and fast dissolution in the digestive tract. Other objects of the present invention will occur to those skilled in the subject art after reading the following detailed description. DETAILED DESCRIPTION OF THE INVENTION
The granules used to make the tablets of the present invention are prepared from low density alkali earth metal salts, low density water soluble carbohydrates and mixtures thereof. The low density alkali earth metal salts of the present invention are known to those skilled in the art. Non-limiting examples of alkali earth metal salts include calcium carbonate, calcium hydroxide, magnesium carbonate, magnesium hydroxide, magnesium silicate, magnesium aluminate, aluminum hydroxide or aluminum magnesium hydroxide. A particular alkali earth metal salt useful for making an antacid tablet is calcium carbonate. Water soluble low density carbohydrates of the present invention are known to those skilled in the art. The water soluble low density carbohydrates are preferably highly porous and can be selected from a high moldability or low moldability type. Preferably, the water soluble low density carbohydrate is one that has a quick disintegration and dissolution rate in the buccal cavity and a high moldability to give adequate hardness when produced by compression molding such as tableting. High moldability type water soluble carbohydrates are selected from the group consisting of maltose, maltitol and sorbitol. Low moldability type water soluble carbohydrates are selected from the group consisting of mannitol, glucose, sucrose and xylitol.
An example of a water soluble low density carbohydrate that exhibits adequate particle size distribution used to make the granules according to the present invention is Sorbitol Instant, available from E.M. Industries, Inc. Hawthorne, N.Y. Sorbitol Instant consists of very loosely packed randomly oriented, interwoven filamentary crystals. These crystals allow smaller sized drug substances to be entrapped in the filamentary matrix of the Sorbitol Instant crystals. The as is density of Sorbitol Instant, prior to being processed according to the present invention, is about 0.38 to about 0.46 gm/ml. The tapped density is about 0.45 to about 0.50 gm/ml. Sorbitol Instant can be used with and without low density alkali earth metal salts.
An example of a low density alkali earth metal salt useful for making the granules according to the present invention is extra light calcium carbonate available from Specialty Minerals Inc., Adams, Maine. The density of the extra light calcium carbonate, prior to being processed according to the present invention, is about 0.37 gm/ml.
The granules used to make the tablets according to the present invention are made by either spray drying or pre-compacting the raw materials. Prior to being processed into granules by either process, the density of the alkali earth metal salts useful in the present invention ranges from about 0.3 grams/ml to about 0.55 grams/ml, preferably about 0.35 grams/ml to about 0.45 grams/ml, even more preferably about 0.37 grams/ml to about 0.42 grams/ml. The density of the carbohydrate depends upon the mesh size and the final process used to produce the carbohydrate
The Spray Drying Process
The spray drying process used to make the granules is a conventional process known to those skilled in the art. The raw materials are slurried in deionized water. The slurry is transferred into the spray dryer. The spray drying parameters can be adjusted depending upon the raw materials used. The spray drying of a calcium carbonate/modified starch blend is performed using an inlet temperature of 190 °C +/- 5 °C and an outlet temperature of 100 °C +/- 5 °C. The final density of the material after spray drying will vary depending upon the process used to produce the product. The Pre-compacting Process
The pre-compacting or pre-compressing process for making the granules can be accomplished by applying a force to the raw material. That is, the raw material is in the from of particles that have a low starting density. A low starting density is from about 0.1 grams/ml to about 1.0 grams/ml. The material is subjected to a compressive force that produces a material with a density higher than the starting density.
One method of applying the force is by processing the material in the Gerteis GMP Roller Compactor, available from Gerteis Macshinen, Jona, Switzerland. Another compactor useful in the pre-compressing process is a Chilsonator made by the Fitzpatrick Co., Elmhurst, 111. The compactors work by feeding the powdered material through rollers. There are five variables that can effect the density and uniformity of the compacted material when processed by the Gerteis machine. Specifically, the force speed, the gap between the rollers, the speed of the rollers, the speed of the oscillating granulator and the mesh size of the screen can be varied depending upon the properties of the raw material and the properties desired in the compacted material.
The compactor can be run at a force speed of from about 1.0 KN/Cm to about 9.0 KN/Cm, preferably about 1.0 KN/Cm to about 5.0 KN/Cm, even more preferably about 1.5 KN/Cm to about 2.5 KN/Cm. The gap between the rollers in the compactor is set between about 2 mm to about 6 mm. The roller speed is from about 4 rpm to about 8 rpm. The oscillator and the mesh screen can be adjusted to deliver the mesh size profile desired.
The density of the granules that result from either the spray drying or pre- compaction process will vary depending upon the density of the materials prior to processing. For example the density of an extra light calcium carbonate increased from 0.37 grams/ml to 0.41 grams/ml after pre-compaction. Both spray drying and pre-compaction increase the density of the particles sufficient to compress them into structurally sound tablets capable of rapid disintegration upon chewing. The pre- compressed raw materials are sized to obtain a specific mesh size profile that closely matches the mesh size profile of the other ingredients used in the tablet.
Tablet Preparation
The granules made by either the spray drying or pre-compacting processes are mixed with excipients and compressed into tablets using conventional tablet making machinery. The granules can be combined with a variety of carriers including low density, high moldability saccharides, low moldability saccharides, polyol combinations, and then directly compressed into a tablet that exhibits an improved dissolution and disintegration profile.
The tablets according to the present invention have a hardness of about 2 to about 6 scu. Tablets within this hardness range disintegrate or dissolve rapidly when chewed. Additionally, the tablets rapidly disentegrate in water. On average, a 1.1 to
1.5 gram tablet disintegrates in 1-3 minutes without stirring. This rapid disintegration facilitates delivery of the active material. The granules used to make the tablets can be mixtures of low density alkali earth metal salts or carbohydrates. For example, a mixture of alkali earth metal salts includes a combination of calcium carbonate and magnesium hydroxide. Similarly, a tablet can be prepared according to the methods of the present invention that incorporates the use of A) spray dried extra light calcium carbonate/maltodextrin, B) magnesium hydroxide and C) a eutectic polyol combination including Sorbitol Instant, xylitol and mannitol. These materials have been combined to produce a low density tablet that dissolves very readily and promotes the fast disintegration of the active ingredient. Additionally, the pre-compacted and spray dried granules can be combined in the same tablet.
The tablets of the present invention optionally contain pharmaceutically active ingredients. An active ingredient useful in the present invention can be any form, such as solid, particulate, granular, crystalline, oily or solution. The active ingredient for use in the present invention may be a spray dried product or an adsorbate that has been pre-compacted to a harder granular form that reduces the medicament taste. A pharmaceutical active ingredient for use in the present invention may be spray dried with a carrier that prevents the active ingredient form being easily extracted from the tablet when chewed.
The active ingredient may be a medicament drug that is selected from a wide variety of drugs and their acid addition salts. Both organic and inorganic salts may be used provided the drug maintains its medicament value. The active ingredient may be at least one member selected from the group consisting of nourishing and health- promoting agents, antipyretic agents, analgesic agents, antiinflammatory agents (including NSAIDS), antipsychotic drugs, antianxiety drugs, antidepressants, hypnotic-sedative agents, spasmolytics, gastrointestinal agents (HI or H2 receptor antagonists and proton pump inhibitors), antacids, antitussives, expectorants, antihistamines, cardiotonics, antiarrhythmic drugs, antiemetic, antinauseant, diuretics, antihypertensive drugs, vasoconstrictors, coronary vasodilators, antibiotics, vasodilators, chemotherapeutic drugs, antidiabetic agents, drugs for osteoporosis, skeletal muscle relaxants, and mixtures thereof. In addition to being added to the tablets of the present invention, the medicament drug itself can be processed by the pre-compaction process to achieve an increased density prior to being incorporated into the formulation.
The pre-compaction process used in the present invention can be used to deliver poorly soluble pharmaceutical materials so as to improve the release of such pharmaceutical materials over traditional dosage forms. This could allow for the use of lower dosage levels to deliver equivalent bioavailable levels of drug and thereby lower toxicity levels of both currently marketed drug and new chemical entities. Poorly soluble pharmaceutical materials can be used in the form of nanoparticles, which are nanometer-sized particles.
In addition to the active ingredient and the granules prepared from low density alkali earth metal salts and/or water soluble carbohydrates, the tablets can be formulated using conventional carriers or excipients and well established pharmaceutical techniques. Conventional carriers or excipients include, but are not limited to, diluents, binders, adhesives (i.e., cellulose derivatives and acrylic derivatives), lubricants (i.e., magnesium or calcium stearate, vegetable oils, polyethylene glycols, talc, sodium lauryl sulphate, polyoxy ethylene monostearate), disintegrants, colorants, flavorings, preservatives, sweeteners and miscellaneous materials such as buffers and adsorbents. In addition to tablets, the particles made by the process of the present invention can also be incorporated into aerosols, topical products, confections and chewing gums. The preparation of confectionery and chewing gum products is historically well known and has changed very little over the years. Thus, for example, the granules prepared from low density inactive ingredients may be combined with a binding agent (e.g., polyvinylpyrrolidone or hydroxypropyl methylcellulose) and other suitable excipients such as fillers (e.g., sugars such as lactose, sucrose, dextrose, fructose, maltose and mannose, preferably fructose and mannose, or sugar alcohols such as sorbitol, xylitol and mannitol). Tablets may be obtained by compressing the granules with suitable tabletting aids such as lubricants (e.g., magnesium stearate) and additional binder. Cast chewable tablets may be prepared by incorporating the granules in one or more low melting point fatty bases such as triglyceride bases. Compressed tablet lozenges can also be prepared. In addition to the granules, they generally contain sugars in amounts up to 95%> and typical tablet excipients such as binders and lubricants as well as flavors, colorants and so forth. The lozenges may be made of soft confectionery materials such as those contained in nougat. These materials contain two primary components, namely a high boiling syrup such as corn syrup or the like, and a relatively light textured frappe, generally prepared from gelatin, egg albumen, milk proteins such as casein, and vegetable proteins such as soy protein, and the like. The frappe is generally relatively light, and may, for example, range in density from about 0.5 to about O.7gm/ml. By comparison, the high boiling syrup, or "bob syrup", is relatively viscous and possesses a higher density, and frequently contains a substantial amount of sugar.
Conventionally, the final nougat composition is prepared by the addition of the "bob syrup" to the frappe under agitation, to form the basic nougat mixture. Further ingredients such as flavorings, oils, additional sugar and the like may be added thereafter also under agitation. A general discussion of the composition and preparation of nougat confections may be found in B.W. Minifie, CHOCOLATE, COCOA AND CONFECTIONERY: Science and Technology, 2nd edition, AVI Publishing Co., Inc., Westport, Connecticut, (1980), at Pages 424-425.
A general discussion of the lozenge and chewable tablet forms of confectionery may be found in H.A. Lieberman and L. Lachman, Pharmaceutical
Dosage Forms: Tablets Volume 1, Marcel Dekker, Inc., New York, N.Y. at pages 289 to 466.
In the instance where auxiliary sweeteners are utilized, the present invention contemplates the inclusion of those sweeteners well known in the art, including both natural and artificial sweeteners. Thus, additional sweeteners may include, among others, water-soluble sweetening agents such as monosaccharides, disaccharides and polysaccharides such as xylose, ribose, glucose, mannose, galactose, fructose, dextrose, sucrose, sugar, maltose, partially hydrolyzed starch, or corn syrup solids and sugar alcohols such as sorbitol, xylitol, mannitol and mixtures thereof; water- soluble artificial sweeteners such as the soluble saccharin salts, i.e., sodium, or calcium saccharin salts, cyclamate salts, acesulfam-K and the like, and the free acid form of saccharin and dipeptide based sweeteners such as L-aspartyl-phenylalanine methyl ester and materials described in U.S. Patent No. 3,492, 131 and the like.
In general, the amount of sweetener will vary with the desired amount of sweeteners selected for a particular tablet composition. Suitable flavorings include both natural and artificial flavors, and mints such as peppermint, menthol, artificial vanilla, cinnamon, various fruit flavors, both individual and mixed, essential oils (i.e. thymol, eculyptol, menthol and methyl salicylate) and the like are contemplated. The flavorings are generally utilized in amounts that will vary depending upon the individual flavor, and may, for example, range in amounts of about 0.5% to about 3% by weight of the final composition weight.
The colorants useful in the present invention, include the pigments such as titanium dioxide, that may be incorporated in amounts of up to about 1% by weight, and preferably up to about .6% by weight. Also, the colorants may include other dies suitable for food, drug and cosmetic applications, and known as F.D. & C. dyes and the like. The materials acceptable for the foregoing spectrum of use are preferably water-soluble. Illustrative examples include indigoid die, known as F.D. & C. Blue No. 2, which is the disodium salt of 5,5'indigotindisulfonic acid. Similarly, the dye known as F.D. & C. Green No. I, comprises a triphenylmethane dye and is the monosodium salt of 4-[4-Nethyl-p-sulfobenzylamino)diphenylmethylene]-[l-(N- ethyl-N-p-sulfoniumbenzyl)- 2,5-cyclohexadienimine], A full recitation of all F.D. & C. and D. & C. and their corresponding chemical structures may be found in the Kirk-Othmer Encyclopedia of Chemical Technology, in Volume 5, at Pages 857-884, which text is accordingly incorporated herein by reference. EXAMPLES
The following examples are provided to further illustrate the present invention. These examples are intended to be exemplary and are not exhaustive or limiting.
Examples 1-7 and Comparative Example 1
Examples 1-7 are examples of tablets made from particles produced by the spray drying method. Each of the examples uses a blend of extra light calcium carbonate with starch or maltodextrin and a sorbitol or polyol blend carrier. The particles are mixed with the carrier, magnesium stearate, PEG 8000 (a polyethylene glycol lubricant), flavor, and sweetener. The mixture is made into tablets using a standard laboratory tablet press. Comparative Example 1 uses a heavy calcium carbonate available from
Specialty Minerals, Inc., Adams, MA. The density of the heavy calcium carbonate is 0.85 grams/ml. The tablet produced with the heavy calcium carbonate had an unacceptable mouthfeel.
Table I shows the formulas of Example 1-7 and Comparative Example 1, in grams and %wt/wt. Table I also includes a description of the tablets made from these examples. Examples 1-7 demonstrate that at similar hardness levels and similar saccharide carriers, tablets produced with spray dried calcium carbonate exhibit a lower tablet density and a better mouthfeel. The product produced with extra light calcium carbonate and spray dried with Modified Starch Miracap is a preferred product for low density and superior mouthfeel when Sorbitol is used as the carrier.
The use of magnesium hydroxide directionally reduces the density of the resultant tablets. Examples 8-13
Examples 8-13 are tablets made with pre-compacted particles of calcium carbonate. The density of the calcium carbonate prior to pre-compaction is 0.37/ml.
Table II shows the formulas of the tablets, the pre-compaction conditions, the mesh size and density of the pre-compacted calcium carbonate, the mesh size and density of the tablet mixture, and the tablet results. The tablets are made using the same process described above for Examples 1-7. Throughout all of the tables, data is not included for some of the examples because the tests were not performed on all of the examples.
Examples 8-13 all produced tablets with acceptable mouthfeel that rapidly disintegrated when chewed. Examples 8-9 are produced with extra light calcium carbonate pre-compacted at the lowest force speed, at the widest gap and the fastest speed. These tablets provide an acceptable product with a low density, superior mouthfeel and excellent reproducibility when using either Sorbitol Instant or Cerelose 2023, a dextrose available from Corn Products, as the saccharide carrier. Examples 14-17
Examples 14-17 are tablets produced by first pre-compacting extra light calcium carbonate and using a combination of Sorbitol Instant and Cerelose 2023 as the carrier. The tablets made from these examples all rapidly disintegrated when chewed. The results indicate that a cohesive, fast chew tablet can be produced using various ratios of Sorbitol Instant and Cerelose 2023 as the carrier. The results are summarized in Table III. Examples 18-20 and Comparative Examples 2-3
Examples 18-19 are tablets made with combinations of pre-compacted and non-compacted calcium carbonate combined with either Sorbitol Instant or Cerelose
2023 to provide satisfactory fast chew tablets. Example 20 is a tablet made with only pre-compacted calcium carbonate and Cerelose 2023 as the carrier. The pre- compaction conditions for Examples 18-20 are a force of 7 KN/Cm, a gap of 2.0 mm and a roller speed of 3.0 rpm. Comparative Example 2 shows the use of a regular sorbitol as the carrier.
Comparative Example 3 shows the use of only non-compacted calcium carbonate. Both comparative Examples 2 and 3 can not be made into tablets because the powder mixture did not flow evenly into the tablet machine. This produced inconsistent tablet weights. The results are summarized in Table IV. Examples 21-26
Examples 21 and 22 show the use of a pre-compacted calcium carbonate with a pre-compacted carrier. Example 21 uses dextrose and Example 22 uses sorbitol, respectively, as the carrier. All the ingredients are compacted at a force speed of 2 KN/cm, a gap of 4 mm and a roller speed of 6 rpm. Examples 23 and 24 show the use of spray dried calcium carbonate combined with maltodextrin or magnesium hydroxide and sorbitol. The magnesium hydroxide added to Example 23 is not spray dried. Example 25 shows the use of only pre-compacted calcium carbonate with no carrier. The calcium carbonate in Example 25 is compacted at a force speed of 2 KN/Cm, a gap of 4 mm and a roller speed of 6 rpm. Example 26 shows the use of pre-compacted calcium carbonate using the same pre-compacting conditions as
Example 25 and a non-compacted sorbitol carrier. All of Examples 21-26 are acceptable, fast chew tablets. The results are summarized in Table V. Examples 27-33 and Comparative Examples 4-5
Examples 27-33 are additional examples of tablets made with combinations of pre-compacted raw materials. Example 27 is made with low lead calcium carbonate and dextrose. Example 28 is made with low lead calcium carbonate and sorbitol. Example 29 is made with regular calcium carbonate and dextrose. Example 30 is made with regular calcium carbonate and sorbitol. Example 31 is made with regular calcium carbonate and non-pre-compacted spray dried sorbitol. Example 32 is made with regular calcium carbonate combined with starch, aspartame and flavor and dextrose. Example 33 is made with regular calcium carbonate combined with starch, aspartame and flavor and sorbitol. Comparative Example 4 is made with regular calcium carbonate and sorbitol. Comparative Example 4 did not flow well into the punch. It is believed that the mesh size of the calcium carbonate was too fine to provide a good flow. Comparative Example 5 is made with a combination of non- pre-compacted calcium carbonate, starch, aspartame and flavor and pre-compacted sorbitol. The powder was too fine for proper flow in the tableting machine. The tablet formulas and mesh size of the tablet mixtures are summarized in Table VI. Examples 34-38
Examples 33-38 show the mesh size of various ingredients before and after pre-compaction. Tables VII and VIII show the mesh size before and after pre- compaction, respectively.
While the invention has been described in detail and with reference to specific examples thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.
TABLE I
Example No.: 1 2 3 4
Ingredient grams %wt/wt grams %wt/wt grams %wt/wt grams %wt/wt
Calcium Carbonate/ 333.33 69.44 333.33 69.44 833.33 69.44 833.33 69.44
Starch Blend1
Calcium Carbonate/
Maltodextrin Blend2
Calcium
Carbonate/ Corn Starch
Blend3
Magnesium Hydroxide
Polyol Combination4 138.27 28.81 345.67 28.81
Sorbitol Instant 138.27 28.81 345.67 28.81
Peppermint Bitter
Trusil Nat Peppermint 2.88 0.60 2.88 0.60 7.20 0.60 7.20 0.60
Mg. Stearate 2..16 0.45 2.16 0.45 5.40 0.45 5.40 0.45
PEG 8000 3.20 0.67 3.20 0.67 8.00 0.67 8.00 0.67
Aspartame 0.16 0.03 0.16 0.03 0.40 0.03 0.40 0.03
TOTAL 480.00 100.00 480.00 100.00 1200.00 100.00 1200.00 100.00
Tablet Results
Capping None None None None
Sticking None None None None
Diameter (inches) 0.63 0.63 0.63 0.63
Weight 1.17 1.20 1.22 1.26
Thickness 0.217 0.205 0.203 0.190
Hardness 3.50 3L5 3.00 4.0
Density (grams cubic inch) 17.30 18.78 19.29 21.26 1
TABLE I (continue d)
Example No.: 5 6 7 Comparative j Example grams %wt/wt grams %wt/wt grams ( oWt/wt grams c /όwt/wt
Calcium Carbonate/ 833.33 69.44
Starch Blend1
Calcium Carbonate/ 171.875 57.29 171,88 57.29
Maltodextrin Blend2
Calcium Carbonate /Corn 833.33 69.44
Starch Blend3
Magnesium Hydroxide 27,50 9.17 27-5 9.17
Polyol Combination4 95.025 31.68 95.32 31.77 346.67 28.81
Sorbitol Instant 138.27 28.81
Peppermint Bitter 2.15 .72
Trusil Nat Peppermint 1.80 0.60 2.88 0.60 7.20 0.60
Mg. Stearate 1.43 0.48 1.40 0.47 2.15 0.45 5.40 0.45
PEG 8000 2.02 0.67 2.00 0.67 3.20 0.67 8.00 0.67
Aspartame 0.10 0.03 0.16 0.03 0.40 0.03
TOTAL 300.00 100.00 300.00 100.00 480.00 100.00 1200.00 100.00
Tablet Results
Capping None None None None
Sticking None None None None
Diameter (inches) 0.63 0.63 0.63 0.63
Weight 1.234 1.22 1.22 1.21
Thickness 0.244 0.243 0.236 0.216
Hardness 3.05 2-3 3.0 3.0
Density (grams cubic inch) 16.25 16.11 16.73 17.83
1 Extra light calcium carbonate with Miracap modified starch in a 90/10 ratio.
2 Extra light calcium carbonate with maltodextrin in a 90/10 ratio.
3 Heavy calcium carbonate with corn starch in a 90/10 ratio.
4 A combination ofsorbitol/xylitol/mannitol in a 92/5/3 ratio.
TABLE II
Example No: 8 9 10 11 12 13
Ingredient grams % t/ t grams %wt wt grams %wt/wt grams c /oWt wt grams %wt wt grams %wt wt
Pre-compacted 750.00 82.50 750.00 52.94 750.00 62.50 750.00 52.94 750.00 62.50 750.00 62.50
CaCOs
Sorbitol Instant 429.00 35.75 429.00 35.75 429.00 35.75 429.00 35.75
Trusil Nat 7.20 0.60 7.20 0.51 7.20 0.51
Peppermint #4451
Trusil Nat 7.20 0.60 7.20 0.51 7.20 0.51
Peppermint #3951
Magnesium Stearate 5.40 0.45 5.40 0.38 5.40 0.45 5.40 0.38 5.40 0.38 5,40 0.38
PEG 8000 5.00 0.67 8.00 0.56 8.00 0.67 8.00 0.56 8.00 0.56 8.00 0.56
Aspartame 0.40 0.03 0.40 0.03 0.40 0.03 0.40 0.03 0.40 0.03 .40 0.03
Cerelose 2023 645.67 45.58 645.67 45.58
Total Wt/ Tablet (mg) 1200.00 100.00 1416.67 100.00 1200.00 100.00 1416.67 100.00 1200.00 100.00 1200.00 100.00
Tablet Mixture
Mesh Size % % % % % %
On 20 10.27 4.31 14.60 5.90 12.00
On 40 67.73 29.98 61.10 40.00 56.90
On 60 23.66 30.66 17.700 27.40 24.04
On 80 4.11 18.92 2.800 16.00 4.61
On 100 1.17 6.26 0.900 5.40 1.18
Thru 100 1.35 9.61 2.700 9.60 3.22
Density gm/ml as is] 0.483 0.51 0.529 06.31 0.520
Density tapped 100 x 0.663 0.756 0.6 0.789 0.675
Figure imgf000020_0001
TABLE III
Example No; 14 15 16 17
Ingredient grams %wt/wt grams %wt wt grams %wt/wt grams %wt t
CaC03 Extra Light 750.00 52.94 750.00 52.94 750.00 52.94 750.00 52.94
Sorbitol Instant 345.67 24.40 240.00 16.94 120.00 8.47 0.00 0.00
Trusil Nat Peppermint 7.20 0.51 7.20 0.51 7.20 0.51 7.20 0.5 ϊ
Magnesium Stearate 5.40 0.38 5.40 0.38 5.40 0.38 5.40 0.38
PEG 8000 8.00 0.56 8.00 0.56 8.00 0.56 8.00 0.56
Aspartame 0.40 0.03 0.40 0.03 0.40 0.03 0.40 0.03
Cerelose 2023 300.00 21.18 405.67 28.64 525.67 37.11 645.67 45.58
Total Wt/ Tablet (mg) 1416.67 100.00 1416.67 100.00 1416.67 100.00 1416.67 100.00
Pre-Compacting Conditions
Force Speed KN/Cm 7 7 7 7
Gap MM 3 3 3 3
Roller Speed rpm 3 3 3 3
Tablet Results
Capping None None None None
Sticking None None None None
Diameter (inches) 0.63 0.63 0.63 0.63
Weight (grams/tablet) 1.41 1.42 1.42 J.41
Thickness (inches) 0.223 0.221 0.22 0.214
Hardness (scu) 3-4 3-4 3-4 3-4
Density (grams cu. inch) 20.38 20.56 20.45 21.23
Figure imgf000021_0001
Figure imgf000022_0001
Figure imgf000022_0002
TABLE N
Example o: 21 23 23 24 25 26
Ingredient grams %wt wt grams %wt/wt grams %wt/wt grams %wt/wt grams %wt/w grams %wt/w t t
CaC03 Extra Light (pre- 750,00 52.94 750.00 62.50 750.00 97.28 750.00 62,47 compacted)
CaCOa/Maϊtσdexttϊn 687.52 57.29
(80/20)
Dextrose Very Fine (pre- 645.57 45.58 compacted)
CaCOs / Mg(QH}2 / Sorbitol 1179.6 98,3
(42.3/8.5/49.2)
Sorbitol Instant 429.00 35.73
Sorbitol
(non-compacted)
Sorbitol Very Fine (pre- 429.00 35.75 compacted) '
Trusil Nat Peppermint 7.20 0.51 7.20 0.60 7.20 0.93 7.20 0.60
Magnesium Hydroxide 110.00 9.17
Magnesium Stearate 5.40 0.38 5.40 0.45 5.60 0.47 5.2 0.43 5.40 0.70 5.40 0.45
PEG 8000 8.00 0.56 8.00 0.67 8.00 0.66 7.4 0.62 8.00 1.04 8.00 0.67
Peppermint Bitter 7.20 0.60 7.8 0.65
Polyol Combination 381.28 31.78
Aspartame 0.40 0.03 0.40 0.03 0.40 .03 0.40 0.05 1.00 0.08
Total Wt/ Tablet (mg) 1416.67 100.00 1200.00 100.00 1200.00 100.00 1200.0 100.00 771.00 100.0 1200.60 100.00
A non-spray dried, non-compacted sorbitol, available from SPI Inc. 2 Sorbitol Instant/Xylitol/ Mannitol Ratio-92/5/3
Figure imgf000024_0001
Figure imgf000024_0002
Figure imgf000025_0001
Figure imgf000026_0001
Figure imgf000027_0001
Figure imgf000028_0002

Claims

What is claimed is:
1. A process for making particles comprising: providing a paniculate material including particles having a starting density, and applying a force to the particulate material to produce particles having an increased density.
2. The process according to claim 1, wherein the starting density is about 0.1 grams/ml to about 1.0 grams/ml and the increased density is about 0.2 grams/ml to about 1.2 grams/ml.
3. The process according to claim 1, wherein the particulate material is selected from the group consisting of carbohydrates, alkali earth metal salts, pharmaceutically active ingredients and mixtures thereof.
4. The process according to claim 3, wherein the alkali earth metal salts are selected from the group consisting of calcium carbonate, calcium hydroxide, magnesium carbonate, magnesium hydroxide, magnesium silicate, magnesium aluminate, aluminum magnesium hydroxide, aluminum hydroxide and mixtures thereof.
5. The process according to claim 3, wherein the carbohydrates are selected from the group consisting of maltose, maltitol, sorbitol, dextrose, mannitol, glucose, sucrose, xylitol and mixtures thereof.
6. The process according to claim 1, wherein the force applied to the particulate material is about 1.0 KN/Cm to about 9.0 KN/Cm.
7. Particles made by the process according to claim 1.
8. Particles made by the process according to claim 2.
9. A process for making a fast chewing tablet comprising: providing a particulate material including particles having a starting density, applying a force to the particulate material to produce particles having an increased density, and compacting the particles to form a tablet.
10. The process according to claim 9, wherein the starting density is about 0.1 grams/ml to about 1.0 grams/ml and the increased density is about 0.2 grams/ml to about 1.2 grams/ml.
11. The process according to claim 9, wherein the particulate material is selected from the group consisting of carbohydrates, alkali earth metal salts and mixtures thereof.
12. The process according to claim 11, wherein the alkali earth metal salts are selected from the group consisting of calcium carbonate, calcium hydroxide, magnesium carbonate, magnesium hydroxide, magnesium silicate, magnesium aluminate, aluminum magnesium hydroxide, aluminum hydroxide and mixtures thereof.
13. The process according to claim 11, wherein the carbohydrates are selected from the group consisting of maltose, maltitol, sorbitol, dextrose, mannitol, glucose, sucrose, xylitol and mixtures thereof.
14. The process according to claim 9, wherein the force applied to the particulate material is about 1.0 KN/Cm to about 9.0 KN/Cm.
15. The process according to claim 9, wherein the tablet has a hardness of about 1 to about 8 scu.
16. The tablet made by the process according to claim 9.
17. The tablet made by the process according to claim 10.
18. A process for making a fast chewing tablet comprising: providing calcium carbonate having a starting density, spray drying the calcium carbonate to produce particles of calcium carbonate having an increased density, and compacting the particles of calcium carbonate having an increased density to from a tablet.
19. The process according to claim 18, wherein the starting density is from about 0.1 grams/ml to about 0.65 grams/ml and the increased density is from about 0.3 grams/ml to about 0.8 grams/ml.
20. The tablet made by the process according to claim 18.
PCT/US1998/008821 1997-05-20 1998-05-04 Fast-dissolving tablets and methods of their manufacture by direct compression WO1998052541A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU71726/98A AU7172698A (en) 1997-05-20 1998-05-04 Fast-dissolving tablets and methods of their manufacture by direct compression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4721797P 1997-05-20 1997-05-20
US60/047,217 1997-05-20

Publications (1)

Publication Number Publication Date
WO1998052541A1 true WO1998052541A1 (en) 1998-11-26

Family

ID=21947717

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/008821 WO1998052541A1 (en) 1997-05-20 1998-05-04 Fast-dissolving tablets and methods of their manufacture by direct compression

Country Status (4)

Country Link
US (1) US5939091A (en)
AU (1) AU7172698A (en)
WO (1) WO1998052541A1 (en)
ZA (1) ZA984229B (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085134A1 (en) * 2000-05-12 2001-11-15 Emcure Pharmaceuticals Ltd Pharmaceutical solid compositions and process for the production of mouth dissolving tablets
EP1295595A1 (en) * 2000-06-30 2003-03-26 Yamanouchi Pharmaceutical Co. Ltd. Tablet rapidly disintegrating in mouth and process for producing the same
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
WO2005115342A1 (en) * 2004-05-24 2005-12-08 Nycomed Pharma As Particulate comprising a calcium-containing compound and a sugar alcohol
WO2006092727A2 (en) * 2005-03-04 2006-09-08 Nycomed Pharma As Process for the production of calcium compositions in a continuous fluid bed
WO2007065441A1 (en) * 2005-12-07 2007-06-14 Nycomed Pharma As Film-coated and/or granulated calcium-containing compounds and use thereof in pharmaceutical compositions
WO2007065440A1 (en) * 2005-12-07 2007-06-14 Nycomed Pharma As Pre-compacted calcium-containing compositions
US7799342B2 (en) 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
US8828435B2 (en) 2005-04-08 2014-09-09 Lingual Consegna Pty Ltd Buccal delivery system
US9839610B2 (en) 2008-07-04 2017-12-12 Roquette Freres Orodispersible mannitol

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US6296868B1 (en) * 1998-11-19 2001-10-02 Advanced Technology Pharmaceuticals Corporation Chewable tablets containing mannitol and aspartame
FR2787110B1 (en) * 1998-12-11 2001-02-16 Roquette Freres SORBITOL PULVERULENT AND PROCESS FOR THE PREPARATION THEREOF
AU3221401A (en) * 1999-11-30 2001-06-12 Rajesh Jain Fast dissolving composition with prolonged sweet taste
FR2803720B1 (en) 2000-01-18 2004-10-22 Roquette Freres DEXTROSE-BASED LOZENGES AND THEIR MANUFACTURING METHOD
US6572887B2 (en) * 2000-05-01 2003-06-03 National Starch And Chemical Investment Holding Corporation Polysaccharide material for direct compression
US20030185886A1 (en) * 2000-05-26 2003-10-02 Hanmi Pharm. Co., Ltd. Process for the preparation of rapidly disintegrating tablet
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US6544552B2 (en) 2001-01-11 2003-04-08 Particle And Coating Technologies, Inc. Method of producing porous tablets with improved dissolution properties
US20030022912A1 (en) * 2001-02-08 2003-01-30 Martino Alice C. Rapid-onset medicament for treatment of sexual dysfunction
MXPA04007169A (en) * 2002-01-25 2004-10-29 Santarus Inc Transmucosal delivery of proton pump inhibitors.
CA2475092C (en) 2002-02-04 2012-05-01 Christian F. Wertz Nanoparticulate compositions having lysozyme as a surface stabilizer
DE60308647T2 (en) * 2002-02-07 2007-08-09 Pharmacia Corp. PHARMACEUTICAL FORM FOR MUCOSAL ADMINISTRATION
AU2003209475A1 (en) * 2002-03-07 2003-09-16 Vectura Limited Fast melt multiparticulate formulations for oral delivery
US20040120991A1 (en) * 2002-09-07 2004-06-24 Mars Incorporated Edible films having distinct regions
EP1545521A2 (en) * 2002-10-04 2005-06-29 Pharmacia Corporation Compositions and methods for treating sexual dysfunction
US20060134195A1 (en) * 2002-11-25 2006-06-22 Yourong Fu Mannose-based fast dissolving tablets
CA2517005A1 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
EP1620075B1 (en) 2003-05-07 2020-06-24 Samyang Biopharmaceuticals Corporation Highly plastic granules for making fast melting tablets
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
GB0320854D0 (en) 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
CA2540040C (en) * 2003-10-07 2012-09-11 Andrx Pharmaceuticals Llc Rapidly disintegrating formulation
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US7410532B2 (en) 2005-04-04 2008-08-12 Krichtafovitch Igor A Method of controlling a fluid flow
CA2617557A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
US7811604B1 (en) * 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
EP1986591A1 (en) * 2006-02-10 2008-11-05 LG Household & Health Care Ltd. In-situ melting and gelling tablet composition for oral care
CA2652657A1 (en) * 2006-05-17 2008-11-27 Wm. Wrigley Jr. Company Method of preparing a food product
US20080014228A1 (en) * 2006-07-14 2008-01-17 Olivia Darmuzey Solid form
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
US20090060983A1 (en) * 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
US20090110716A1 (en) * 2007-10-31 2009-04-30 Frank Bunick Orally disintegrative dosage form
US8795724B2 (en) * 2008-06-12 2014-08-05 Universite Laval Modified protein excipient for delayed-release tablet
US8858210B2 (en) 2009-09-24 2014-10-14 Mcneil-Ppc, Inc. Manufacture of variable density dosage forms utilizing radiofrequency energy
US8784781B2 (en) * 2009-09-24 2014-07-22 Mcneil-Ppc, Inc. Manufacture of chewing gum product with radiofrequency
US20110070286A1 (en) * 2009-09-24 2011-03-24 Andreas Hugerth Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
EP2415829A1 (en) * 2010-07-30 2012-02-08 Schaefer Kalk GmbH & Co. KG Dry liquid
AU2011306065B2 (en) * 2010-09-22 2015-03-19 Mcneil-Ppc, Inc. Manufacture of tablets from energy-applied powder blend
US9233491B2 (en) 2012-05-01 2016-01-12 Johnson & Johnson Consumer Inc. Machine for production of solid dosage forms
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
ES2750323T3 (en) 2014-01-10 2020-03-25 Johnson & Johnson Consumer Inc Method for manufacturing a tablet using radio frequency and loss coated particles
EP3069713A1 (en) * 2015-03-20 2016-09-21 Omya International AG Dispersible dosage form
EP3260114A1 (en) 2016-06-21 2017-12-27 Omya International AG Method for the production of a dosage form
EP3260115A1 (en) * 2016-06-21 2017-12-27 Omya International AG Method for the production of a dosage form
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1123336A (en) * 1965-02-12 1968-08-14 Farmaceutici Italia New pharmaceutical form
US4650669A (en) * 1985-07-30 1987-03-17 Miles Laboratories, Inc. Method to make effervescent calcium tablets and calcium tablets produced thereby
WO1993000828A2 (en) * 1991-07-08 1993-01-21 Warner-Lambert Company Stabilized sweetener composition
WO1996023494A1 (en) * 1995-02-02 1996-08-08 Applied Analytical Industries, Inc. Oral compositions of h2-antagonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617638A1 (en) * 1967-05-24 1971-05-13 Miles Lab Tablet binder
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
DE3245170A1 (en) * 1982-12-07 1984-06-07 Merck Patent Gmbh, 6100 Darmstadt IMPROVED SORBITE, METHOD FOR THE PRODUCTION AND USE
US4684534A (en) * 1985-02-19 1987-08-04 Dynagram Corporation Of America Quick-liquifying, chewable tablet
US4855326A (en) * 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
GB8710965D0 (en) * 1987-05-08 1987-06-10 Smith Kline French Lab Pharmaceutical compositions
US5073377A (en) * 1988-11-03 1991-12-17 Miles Inc. Method of preparing oral dosage forms with a granulating composition
DE3927398A1 (en) * 1989-08-19 1991-02-21 Henkel Kgaa Granulating sodium perborate mono:hydrate - by compacting dry with alkali or alkaline earth salt and comminuting used in granular washing and cleaning compsns.
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5244670A (en) * 1991-04-04 1993-09-14 The Procter & Gamble Company Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress
EP0553777B1 (en) * 1992-01-29 2002-04-24 Takeda Chemical Industries, Ltd. Fast dissolving tablet and its production
US5562919A (en) * 1993-05-20 1996-10-08 American Meat Protein Corporation Dried animal plasma as a pharmaceutical excipient for compressed tablet formulation
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5807577A (en) * 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1123336A (en) * 1965-02-12 1968-08-14 Farmaceutici Italia New pharmaceutical form
US4650669A (en) * 1985-07-30 1987-03-17 Miles Laboratories, Inc. Method to make effervescent calcium tablets and calcium tablets produced thereby
WO1993000828A2 (en) * 1991-07-08 1993-01-21 Warner-Lambert Company Stabilized sweetener composition
WO1996023494A1 (en) * 1995-02-02 1996-08-08 Applied Analytical Industries, Inc. Oral compositions of h2-antagonists

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085134A1 (en) * 2000-05-12 2001-11-15 Emcure Pharmaceuticals Ltd Pharmaceutical solid compositions and process for the production of mouth dissolving tablets
EP1295595A1 (en) * 2000-06-30 2003-03-26 Yamanouchi Pharmaceutical Co. Ltd. Tablet rapidly disintegrating in mouth and process for producing the same
EP1295595A4 (en) * 2000-06-30 2008-04-02 Astellas Pharma Inc Tablet rapidly disintegrating in mouth and process for producing the same
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
US7799342B2 (en) 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
JP2008500290A (en) * 2004-05-24 2008-01-10 ニコメド ファーマ エイエス Fine particles containing calcium-containing compound and sugar alcohol
US10357460B2 (en) 2004-05-24 2019-07-23 Takeda As Particulate comprising a calcium-containing compound and a sugar alcohol
US10258576B2 (en) 2004-05-24 2019-04-16 Takeda As Particulate comprising a calcium-containing compound and a sugar alcohol
CN103550178A (en) * 2004-05-24 2014-02-05 武田奈科明有限公司 Particulate comprising a calcium-containing compound and a sugar alcohol
CN101001611B (en) * 2004-05-24 2013-05-22 奈科明制药有限公司 Particulate comprising a calcium-containing compound and a sugar alcohol
NO339208B1 (en) * 2004-05-24 2016-11-14 Takeda Nycomed As Particulate material comprising a calcium-containing compound and a sugar alcohol
KR100898970B1 (en) * 2004-05-24 2009-05-25 니코메드 파마 에이에스 Particulate comprising a calcium-containing compound and a sugar alcohol
EA011746B1 (en) * 2004-05-24 2009-06-30 Никомед Фарма Ас Agglomeration of the calcium-containing compound by means of roller compaction
AU2005247060B2 (en) * 2004-05-24 2010-09-09 Takeda As Particulate comprising a calcium-containing compound and a sugar alcohol
WO2005115342A1 (en) * 2004-05-24 2005-12-08 Nycomed Pharma As Particulate comprising a calcium-containing compound and a sugar alcohol
AU2005247060C1 (en) * 2004-05-24 2011-03-31 Takeda As Particulate comprising a calcium-containing compound and a sugar alcohol
WO2006092727A3 (en) * 2005-03-04 2006-10-26 Nycomed Pharma As Process for the production of calcium compositions in a continuous fluid bed
EA011379B1 (en) * 2005-03-04 2009-02-27 Никомед Фарма Ас Process for the production of calcium compositions in a continuous fluid bed
WO2006092727A2 (en) * 2005-03-04 2006-09-08 Nycomed Pharma As Process for the production of calcium compositions in a continuous fluid bed
US8828435B2 (en) 2005-04-08 2014-09-09 Lingual Consegna Pty Ltd Buccal delivery system
EA015035B1 (en) * 2005-12-07 2011-04-29 Никомед Фарма Ас Pre-compacted calcium-containing compositions
NO340899B1 (en) * 2005-12-07 2017-07-10 Takeda As Film-coated calcium-containing compounds, process for preparation and use thereof in pharmaceutical compositions.
CN101365426B (en) * 2005-12-07 2012-08-08 奈科明制药有限公司 Pre-compacted calcium-containing compositions
US8846101B2 (en) 2005-12-07 2014-09-30 Takeda Nycomed As Film-coated and/or granulated calcium-containing compounds and use thereof in pharmaceutical compositions
US8906411B2 (en) 2005-12-07 2014-12-09 Takeda Nycomed As Pre-compacted calcium-containing compositions
EP2436378A1 (en) * 2005-12-07 2012-04-04 Nycomed Pharma AS Film-coated and/or granulated calcium-containing compounds and use thereof in pharmaceutical compositions
NO20170606A1 (en) * 2005-12-07 2017-04-10 Takeda As Process for the preparation of film-coated calcium-containing compounds and process for the preparation of pharmaceutical tablets or nutritional tablets
EA018744B1 (en) * 2005-12-07 2013-10-30 Никомед Фарма Ас Granulated therapeutically and/or prevention active calcium-containing compound and method for preparation thereof
US9801907B2 (en) 2005-12-07 2017-10-31 Takeda As Film-coated and/or granulated calcium-containing compounds and use therof in pharmaceutical compositions
WO2007065441A1 (en) * 2005-12-07 2007-06-14 Nycomed Pharma As Film-coated and/or granulated calcium-containing compounds and use thereof in pharmaceutical compositions
NO341860B1 (en) * 2005-12-07 2018-02-12 Takeda As Process for Preparation of Film-Coated Calcium-Containing Compounds and Process for the Preparation of Pharmaceutical Tablets or Nutritional Tablets
WO2007065440A1 (en) * 2005-12-07 2007-06-14 Nycomed Pharma As Pre-compacted calcium-containing compositions
US10105314B2 (en) 2008-07-04 2018-10-23 Roquette Freres Orodispersible mannitol
US9839610B2 (en) 2008-07-04 2017-12-12 Roquette Freres Orodispersible mannitol

Also Published As

Publication number Publication date
ZA984229B (en) 1999-11-19
US5939091A (en) 1999-08-17
AU7172698A (en) 1998-12-11

Similar Documents

Publication Publication Date Title
US5939091A (en) Method for making fast-melt tablets
US4687662A (en) Therapeutic effervescent composition
US4327076A (en) Compressed chewable antacid tablet and method for forming same
US8945618B2 (en) Intrabuccally rapidly disintegrating tablet and a production method of the tablets
EP0203768B2 (en) A therapeutic effervescent composition and a method of preparing the same
US5965162A (en) Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom
DE60028536T2 (en) In the oral cavity rapidly disintegrating oral solid administration form
US5895664A (en) Process for forming quickly dispersing comestible unit and product therefrom
EP0561815B1 (en) Directly compressible xylitol and method
US4446135A (en) Chewable antacid tablets
JP2003506399A (en) Means for producing bulking agents with structural integrity
US20100010101A1 (en) Rapid-Melt Compositions and Methods of Making Same
US5935600A (en) Process for forming chewable quickly dispersing comestible unit and product therefrom
JPH0818974B2 (en) Medicinal adsorbate and its manufacturing method
JP5623275B2 (en) Directly tabletable dextrose
JP2012519729A (en) Highly compactable and durable direct compression excipients and excipient systems
US5958445A (en) Oral Formulations of S(+)-etodolac
JP4302770B2 (en) Manufacturing method and apparatus for rapidly dissolving dosage unit and product thereof
JP2000119175A (en) Intraoral rapid disintegrative solid preparation
JPH04234324A (en) Digestable sucralphate tablet
WO2003103713A1 (en) Rapidly disintegrating tablet and process for producing the same
JPH1112162A (en) Tablet rapidly disintegrable in oral cavity and its production
WO1999008656A1 (en) Antacid composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BA BB BG BR CA CN CZ EE GE GW HU ID IL IS JP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998550387

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA